Greenwich LifeSciences Expands GLSI-100 Market

Greenwich LifeSciences announced new patent claims for its immunotherapy GLSI-100, based on statistically significant open label immune response and recurrence rate data from its Phase III clinical trial, FLAMINGO-01. These claims suggest that GLSI-100 clinically benefits non-HLA-A*02 patients, potentially doubling the market for the drug to 88,000 new patients annually in the United States and Europe, and increasing potential revenue to $10 billion per year. The company plans to expand its immune response analysis and has already begun enrolling both HLA-A*02 and non-HLA-A*02 patients in FLAMINGO-01 in the United States, following a review by the United States — Food and Drug Administration. Preliminary analysis from the non-HLA-A*02 arm shows an approximately 80% reduction in recurrence rate, similar to previous Phase IIb trial results.